EndoDiagnosis & ENDOSURE Revolutionize Endometriosis Detection in Canada with 30-Minute Non-Invasive Test
In the past, diagnosing endometriosis required invasive laparoscopic surgery. This often meant that patients endured years of pain and a lower quality of life without a proper diagnosis. The ENDOSURE test offers a non-invasive option, boasting 99% accuracy in detecting all stages of the disease in less than an hour. This bypasses the need for surgical procedures. Learn more about EndoDiagnosis and what they offer by visiting their website.
EndoDiagnosis Founders – Maria Porcellato, Carolyn Plican, Dr. Mary Ellen Haggerty
This development is crucial for addressing a major gap in healthcare. Women suffering from endometriosis symptoms frequently face challenges in receiving the correct diagnosis and treatment. By providing a quick and effective diagnostic tool, ENDOSURE helps healthcare providers make faster, more informed decisions, improving care for those impacted by this chronic illness.
Maria Porcellato, CEO of EndoDiagnosis, stated, "We have seen the desperation in patients, clients, and even our own daughters that comes with undiagnosed endometriosis. Our mission centers on empowering both patients and healthcare teams with the decision-support tools they need to make informed decisions about healthcare."
The ENDOSURE Tier 1 test is designed for women of any age and provides results on the spot without the need for referrals or lab work. Its non-invasive nature not only spares patients from unnecessary surgical procedures but also enables healthcare professionals to concentrate on therapeutic strategies to manage the disease, preserving both quality of life and fertility.
EndoDiagnosis is not just distributing this advanced technology but is also dedicated to ensuring its successful use in clinics throughout Canada. The company offers training and certification for healthcare providers, professional medical education, and awareness programs, along with a provider directory to help patients find testing centers.
This initiative places Canada at the forefront of endometriosis care, allowing healthcare professionals to offer their patients both clarity and hope. Carolyn Plican, COO of EndoDiagnosis, stressed the importance of this development, commenting, "This partnership represents more than a business agreement – it's about validating women's experiences and providing the answers they desperately need. When patients understand the root cause of their symptoms, it reduces stress, creates closure, and empowers them to move forward with effective treatment strategies."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
12 minutes ago
- Bloomberg
Arkansas Governor Seeks to Block Health Insurance Rate Hikes
Arkansas Governor Sarah Huckabee Sanders said she would oppose premium increases from health insurers including Centene Corp., an early sign of the political maneuvering that's likely to follow instability in insurance markets. Some companies are requesting average rate increases of more than 50%, according to the Arkansas Insurance Department.
Fox News
43 minutes ago
- Fox News
Woman survives deadly brain tumor, plus warnings about virus in China
FATAL EPIDEMIC - Cancer deaths are surging due to a common health condition, experts say. Continue reading… DEADLY DRUG - A synthetic opioid stronger than fentanyl is spreading rapidly across the Americas. Continue reading… Fox News LifestyleFox News Health
CBS News
44 minutes ago
- CBS News
Minnesota sees sedative overdose spike: "Naloxone isn't going to help"
By WCCO reporter Ashley Grams The Minnesota Department of Health issued a health advisory last week warning of an increase in overdose cases involving sedatives. Data collected by the department's Minnesota Drug Overdose and Substance Use Surveillance Activity (MNDOSA) project shows just one overdose case where the sedative xylazine was detected. That number jumped to 53 in 2024. Now, the state is tracking another sedative emerging in the drug supply. "Medetomidine, it has been seen in other parts of the country," said Deepa McGriff, the department's epidemiologist supervisor. "It is a veterinary sedative that's not approved for human use, and in 2025 we started to see more detections." The state's Public Health Laboratory started tracking medetomidine in 2024 and this year has seen 12 cases. "Here in Minnesota, we are somewhat insulated, initially, from new substances as they emerge, maybe on the East Coast or West Coast," said Jason Peterson, who supervises the chemical threats and bio monitoring units at the Public Health Laboratory. Peterson says medetomidine was "starting to grow" out on the East Coast. "They do take delays in a lot of times in entering our state, but we are mindful of that and we are mindful of the patterns where drugs typically flow across the country," he said. This increase in sedatives is a dangerous reality for drug users across the state. "Certainly for the subset of people that we work with that are using substances, we do see these things come through," said John Tribbett, the service area director for Avivo's ending homelessness division. "We are at a point unfortunately where you never know what people are getting, and what they end up putting in their body. Tribbett said all of Avivo's teams are trained in overdose reversal. The state's health advisory warns that these sedatives "significantly complicates the treatment of overdose patients." McGriff says the department wants the community and first responders to understand that sedatives may be a factor in an overdose, and how that can impact treatment. "If there's a sedative involved, the Naloxone isn't going to work to reverse that unresponsiveness," McGriff said. "We want to emphasize the need to focus on restoring the breathing of the overdose patients, rather than restoring the consciousness." McGriff said an opioid reversal drug like naloxone should still be used in these cases. Tribbett believes the emergence of medetomidine is a reflection of policy aimed at restricting xylazine. "What we see time and time again is a crackdown on one particular chemical, and then something emerges to replace it," Tribbett said. Some states have made an effort to limit access to xylazine in recent years, including Pennsylvania, which classified xylazine as a Schedule 3 drug. Minnesota's health department says data is still limited when it comes to medetomidine, but awareness is important — something Tribbett agrees with. "Making people aware, helping our teams have the information they need, helping people in the community know what's out there," Tribbett said.
